Protalix BioTherapeutics Schedules Third Quarter 2026 Financial Results and Business Update
Protalix BioTherapeutics (NYSE American: PLX) has announced that it will release its financial results for the third quarter ended September 30, 2026, on November 10, 2026. The company plans to host a conference call and webcast at 8:00 a.m. ET to discuss these results alongside an update regarding recent corporate and regulatory developments. The biopharmaceutical firm, which specializes in plant cell-based expression systems for rare disease therapeutics, will provide insights into its current pipeline and commercial progress. Investors should look for updates on key products such as Elfabrio® and the company's proprietary development programs.
Tickers: $PFE